TusHoldings recently announced that the company plans to sign the Equity Transfer Agreement with two shareholders of Guangdong Xantong, Beijing Xantongyuan Pharmaceutical Technology Co.
, Ltd.
and Li Yinqiang and Guangdong Xantong
.
The company intends to acquire 100% equity of Guangdong Xantong Pharmaceutical held by the transferor at a consideration of RMB 220 million in cash
.
It is reported that Affected by this news, TusPharm opened up sharply the next day and quickly reached the daily limit
.
Regarding this acquisition, TusPharm stated that after receiving 100% equity of Guangdong Xantong, it can further enrich the product line and expand the industrial chain layout by integrating the product and resource advantages of both parties
.
Another person said that the acquisition of the company may be mainly aimed at approval documents, or it may be aimed at the production plant and local market of the acquired company
.
It is reported that Guangdong Xantong holds a total of 16 Chinese medicine approvals, and the dosage forms include tablets, capsules and granules; applicable departments include cardiovascular medicine, endocrinology, gastroenterology, ophthalmology, gastroenterology, infectious diseases, urology,
etc.
Among the 16 traditional Chinese medicine varieties, there are 1 exclusive variety, 1 basic drug catalogue variety, 3 medical insurance category B varieties, and 2 OTC varieties
.
Among them, Yixinshu Tablets is the core product of Guangdong Xiantong, which is used for cardiovascular diseases
.
Xiaotangling tablet is an exclusive variety of Guangdong Xiantong, which is used for diabetes
.
Data shows that in the first quarter of 2022, Guangdong Xantong achieved operating income of 16.
6636 million yuan and net profit of 1.
1742 million yuan; and in 2021, it achieved operating income of 101 million yuan and net profit of 10.
7056 million yuan
.
According to the industry, the active approval transaction market is mainly affected by policy changes
.
Among them, the major advantage of the MAH system is that the marketing authorization (the holder of the drug approval number) is separated from the production enterprise.
Even if you have no production conditions, you can entrust others to produce
.
For drug R&D companies, it is no longer necessary to build a new pharmaceutical factory in order to keep the approval.
For pharmaceutical distributors, they can also hold drug approvals by cooperating with pharmaceutical R&D companies
.
It not only avoids repeated construction, but also optimizes resource allocation
.
Compared with chemical medicine, traditional Chinese medicine has many types of approval documents, and there are a large number of different products of the same type, and there are more choices of tradable products in the market
.
According to the data, as of the first half of 2022, there were 2,426 applications for the transfer of drug approval documents nationwide, of which 1,338 were for traditional Chinese medicines, accounting for 55.
15%; 1,086 were for chemical drugs, accounting for 44.
8%
.
It is understood that for this transaction, TusHoldings is an enterprise engaged in the production and sales of traditional Chinese and Western medicines.
), Yangxin Dingpai Granules and other Chinese patent medicines, as well as large-volume injections, APIs, five-dimensional lysine oral solution and other western medicine preparations
.
Recently, TusHoldings released its performance forecast for the first half of 2022.
The company expects to make a profit of RMB 11 million to RMB 13 million in the first half of 2022, a decrease of 55.
48% to 62.
33% year-on-year
.
The company stated that the main reasons for the decrease in net profit attributable to shareholders of listed companies in the first half of 2022 compared with the same period of the previous year: 1.
During the reporting period, the prices of the company's main products and raw materials increased, resulting in increased costs and a year-on-year decline in gross profit margin
.
2.
During the reporting period, in order to expand the sales market, the company increased marketing efforts, resulting in a year-on-year increase in sales expenses
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
![3-bromodibenzo[b,d]thiophene](https://file.echemi.com/fileManage/upload/cas/822/bb4496d0-decc-11eb-89d6-0255ac100033.png)
